Table 3.

Key features of studies included in NNT and NNH analysis

	Sample size	Dosing		Study duration		Incidence of relapse
	(n)	Range	Dosing interval	Stabilization period	Double-blind period	Active treatment group, n/total, (%)	Placebo group n/total, (%)
Paliperidone palmitate
Hough et al16	410	25–100 mg eqa	4 weeks	33 weeks	Variable range	36/205 (18%)	97/203 (48%)
Pandina et al17	652	25–150 mg eqb	4 weeks	NA	13 weeks	NA	NA
Haloperidol decanoate
Eklund and Forsman18	56	60 mg	4 weeks	15 weeks	48 weeks	2/20 (10%)	16/23 (70%)
Bromperidol decanoate
Smeraldi et al22	20	150 mg	Monthly	NA	6 months	Not mentioned	Not mentioned
Fluphenazine decanoate
Hirsch et al19	81	12–25 mgc	2–4 weeks 8 weeks		15 months	6/36 (17%)	27/38 (71%)
Jolley et al20	54	NAd	4 weeks	2 months	48 months	3/25 (12%)	12/24 (50%)
Odejide and Aderounmu21	53	50 mg	4–8 weeks	2 years	12 months	5/21 (19%)	15/27 (56%)
Dotti et al12 (48 weeks)	20	25–50 mg	monthly	6 months	9 months	1/10 (10%)	3/10 (30%)

Notes:

^aDoses are given monthly and ranges are expressed in terms of mg eq (234 mg paliperidone palmitate = 150 mg eq of paliperidone; 156 mg paliperidone palmitate = 100 mg eq of paliperidone; 78 mg paliperidone palmitate = 50 mg eq of paliperidone);

^bInitial dose on day 1 with 150 mg eq, followed by either 150, 100 or 25 mg eq.

^cMinimum dose 25 mg/month or 12.5 mg/biweekly. No upper limit for dose specified;

^dDose range not specified. Mean dose of fluphenazine decanoate 25.6 mg. Oral haloperidol (5–10 mg/d) allowed for up to 2 weeks to treat prodromal symptoms.

Abbreviation: NA, not available (not reported in primary manuscript).